Current FDA-approved CD19-targeted CAR-T cell therapies use murine-derived scFv (FMC63) and develop humoral and/or cellular immune responses against scFv in some individuals as one of the tumor relapse mechanisms.34 This evidence concerns the gene CD19 and neoplasm.